Abstract 2MO
Background
Savolitinib, a highly selective MET tyrosine kinase inhibitor, has shown promising activity and tolerable safety in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other NSCLCs harboring MET exon14 skipping mutations (METex14+) (Lu, 2021). Here we report the long-term overall survival (OS), exposure and subgroup analysis results.
Methods
In the open-label phase 2 study, eligible pts received oral savolitinib at 600 mg (body weight ≥50 kg) or 400 mg (<50 kg), QD in 21-day cycles. The primary objectives were OS and treatment exposure with a longer follow up time. Subgroup analysis was performed by prior systemic treatment (yes vs. no), NSCLC subtypes (PSC vs. other NSCLCs) and brain metastases.
Results
Of 70 pts enrolled and assigned to treatment (FAS), 25 were diagnosed as PSC and 45 as other NSCLCs, 28 were treatment-naïve and 42 were pretreated, 15 pts had CNS lesions. The data cutoff for final analysis was Jun 28, 2021. Eight pts are still on-treatment and 14 (20%) pts with more than 18-mo treatment. With a median follow up time of 28.4 mo (IQR 26.2–36.3), the median OS (mOS) was 12.5 mo (95%CI 10.5–21.4) in FAS; 18-mo OS rate, 42.1%; 24-mo OS rate, 31.5%. In pretreated and treatment naïve subgroups, 28.6% (12/42) and 46.4% (13/28) were PSC pts, respectively, and mOS was 19.4 mo (95%CI 10.5-31.3) and 10.9 mo (95%CI 7.5–14.0); 18-mo OS rate, 50.4% and 29.7%; 24-mo OS rate, 37.5% and 22.3%; respectively. In PSC and other NSCLC pts, mOS was 10.6 mo (95%CI 4.6–14.0) and 17.3 mo (95%CI 10.6–23.6); 18-mo OS rate, 29.9% and 49.0%; 24-mo OS rate, 25.6% and 34.7%; respectively. Pts with brain metastases had mOS of 17.7 mo (95%CI 10.48–NA), 18-m OS rate 50.0% and 24-m OS rate 35.7%. Grade ≥3 treatment-related adverse events were reported in 32 (45.7%) pts, the most frequent being AST increased (12.9%), ALT increased (10.0%) and peripheral oedema (8.6%). Overall, with prolonged follow-up and exposure, the incidences of AE were similar to previously reported data, and consistent across subgroups.
Conclusions
The updated results further confirm the favorable benefit of savolitinib in pts with METex14+ NSCLC and each subgroup, and the acceptable safety profile.
Clinical trial identification
NCT02897479.
Legal entity responsible for the study
HUTCHMED.
Funding
HUTCHMED.
Disclosure
S. Weiguo: Other, Personal, Officer: HUTCHMED. All other authors have declared no conflicts of interest.
Resources from the same session
3MO - First-line camrelizumab plus carboplatin and paclitaxel for advanced squamous non-small-cell lung cancer: Updated overall survival results from the phase 3 CameL-sq trial
Presenter: Caicun Zhou
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
4MO - Final Overall Survival (OS) Data of Sintilimab Plus Pemetrexed (SPP) and Platinum as First-Line (1L) Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (AMnsqNSCLC) in the Phase 3 ORIENT -11 Study
Presenter: Yunpeng Yang
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
5MO - Patient-reported outcomes (PROs) with 1L durvalumab (D), with or without tremelimumab (T), plus chemotherapy (CT) in metastatic (m) NSCLC: Results from POSEIDON
Presenter: Edward Garon
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
6MO - Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC With PD-L1 tumor proportion score <b>≥</b>50%: KEYNOTE-598 3-year follow-up
Presenter: Delvys Rodriguez Abreu
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
7MO - Oritinib (SH-1028), a third-generation EGFR tyrosine kinase inhibitor in locally advanced or metastatic NSCLC patients with positive EGFR T790M: results of a single-arm phase II trial
Presenter: Caicun Zhou
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
8MO - The efficacy and safety of TQ-B3101 monotherapy in the first line treatment in patients with ROS1 positive non-small cell lung cancer
Presenter: Shun Lu
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
Invited Discussant of 3MO, 4MO, 5MO and 6MO
Presenter: Luis Paz-Ares
Session: Mini Oral session 2
Resources:
Slides
Webcast
Invited Discussant of 2MO, 7MO and 8MO
Presenter: Natasha Leighl
Session: Mini Oral session 2
Resources:
Slides
Webcast
Q&A
Session: Mini Oral session 2
Resources:
Webcast